Free Trial

Humacyte (HUMA) News Today

$7.49
+0.34 (+4.76%)
(As of 04:00 PM ET)
Humacyte (NASDAQ:HUMA) Shares Up 4.9%
Humacyte (NASDAQ:HUMA) Trading Up 4.9%
Humacyte (NASDAQ:HUMA) Receives "Buy" Rating from Benchmark
Humacyte (NASDAQ:HUMA) Receives Buy Rating from Benchmark
Benchmark reaffirmed a "buy" rating and issued a $15.00 price target on shares of Humacyte in a research note on Friday.
Humacyte (NASDAQ:HUMA) Trading 7.3% Higher
Humacyte (NASDAQ:HUMA) Shares Up 7.3%
Humacyte (NASDAQ:HUMA) Hits New 12-Month High at $7.10
Humacyte (NASDAQ:HUMA) Reaches New 1-Year High at $7.10
Humacyte (NASDAQ:HUMA) Stock Price Down 3.4%
Humacyte (NASDAQ:HUMA) Shares Down 3.4%
Humacyte (NASDAQ:HUMA) Trading Down 3.4%
Humacyte (NASDAQ:HUMA) Shares Up 6.2% After Insider Buying Activity
Humacyte (NASDAQ:HUMA) Shares Up 6.2% on Insider Buying Activity
Humacyte (NASDAQ:HUMA) Sees Large Volume Increase
Humacyte (NASDAQ:HUMA) Sees Strong Trading Volume
Humacyte (NASDAQ:HUMA) Shares Gap Up to $5.48
Humacyte (NASDAQ:HUMA) Shares Gap Up to $5.48
Benchmark Co. Keeps Their Buy Rating on Humacyte (HUMA)
Humacyte (NASDAQ:HUMA) Hits New 12-Month High at $5.09
Humacyte (NASDAQ:HUMA) Reaches New 52-Week High at $5.09
Q1 2024 Humacyte Inc Earnings Call
Humacyte (NASDAQ:HUMA) Trading Up 6.2%
Humacyte (NASDAQ:HUMA) Shares Up 6.2%
Humacyte Q1 2024 Earnings Preview
Humacyte (HUMA) to Release Quarterly Earnings on Friday
Humacyte (NASDAQ:HUMA) will be releasing earnings before the market opens on Friday, May 10, Zacks reports.
Humacyte (NASDAQ:HUMA) Trading Up 7.4%
Humacyte (NASDAQ:HUMA) Stock Price Up 7.4%
Oppenheimer Keeps Their Buy Rating on Humacyte (HUMA)
Research Analysts Set Expectations for Humacyte, Inc.'s FY2024 Earnings (NASDAQ:HUMA)
Humacyte, Inc. (NASDAQ:HUMA - Free Report) - Equities research analysts at Cantor Fitzgerald upped their FY2024 earnings per share estimates for Humacyte in a research report issued to clients and investors on Monday, April 1st. Cantor Fitzgerald analyst K. Kluska now expects that the company wil
Humacyte's (HUMA) Overweight Rating Reiterated at Cantor Fitzgerald
Cantor Fitzgerald reissued an "overweight" rating and issued a $7.00 target price on shares of Humacyte in a research report on Monday.
Short Interest in Humacyte, Inc. (NASDAQ:HUMA) Declines By 36.5%
Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) saw a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 3,780,000 shares, a drop of 36.5% from the February 29th total of 5,950,000 shares. Based on an average daily volume of 870,900 shares, the short-interest ratio is presently 4.3 days. Approximately 4.5% of the shares of the company are short sold.
Humacyte's (HUMA) "Buy" Rating Reiterated at Benchmark
Benchmark reaffirmed a "buy" rating and set a $15.00 price target on shares of Humacyte in a research report on Monday.
Q4 2023 Humacyte Inc Earnings Call
Humacyte (NASDAQ:HUMA) Posts Earnings Results
Humacyte (NASDAQ:HUMA - Get Free Report) released its earnings results on Friday. The company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.01. During the same period in the prior year, the company posted ($0.21) EPS.
HUMA Stock Earnings: Humacyte Meets EPS for Q4 2023
Humacyte GAAP EPS of -$0.24 in-line
What Wall Street expects from Humacyte's earnings
Get Humacyte News Delivered to You Automatically

Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter.

WARNING about the death of the U.S. dollar… (Ad)

Where do you turn during times of economic uncertainty? Many elites trust storing their wealth in gold (which has historically boomed when the dollar’s value has plummeted!)

Get Colonial Metals' new Precious Metals Investment Guide.

HUMA Media Mentions By Week

HUMA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

HUMA
News Sentiment

0.54

0.92

Average
Medical
News Sentiment

HUMA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

HUMA Articles
This Week

10

2

HUMA Articles
Average Week

Get Humacyte News Delivered to You Automatically

Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:HUMA) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners